(2021) Activation of mTORC1 at late endosomes misdirects T mobile fate final decision in older people. Sci Immunol Although the new generation of mTOR inhibitors hold good assure for anticancer therapy and they are rapidly moving into medical trials, there are numerous critical challenges that determine their good results in https://juvenall318bgk1.azzablog.com/profile